Prions, prionoids and pathogenic proteins in Alzheimer disease by Ashe, Karen H & Aguzzi, Adriano
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2012
Prions, prionoids and pathogenic proteins in Alzheimer disease
Ashe, Karen H; Aguzzi, Adriano
Abstract: Like patients with prion disease, Alzheimer patients suffer from a fatal, progressive form of
dementia. There is growing evidence that amyloid-￿ (A￿) aggregates may be transmissible similar to prions,
at least under extreme experimental conditions. However, unlike mice infected with prion protein (PrP)
prions, those inoculated with A￿ do not die. The transmission of A￿ and PrP thus differs conspicuously
in the neurological effects they induce in their hosts, the difference being no less than a matter of life and
death. Far from being a mere academic nuance, this distinction between A￿ and PrP begs the crucial
questions of what, exactly, controls prion toxicity and how prion toxicity relates to prion infectivity.
DOI: 10.4161/pri.23061
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-72109
Originally published at:
Ashe, Karen H; Aguzzi, Adriano (2012). Prions, prionoids and pathogenic proteins in Alzheimer disease.
Prion, 7(1):1-5. DOI: 10.4161/pri.23061
www.landesbioscience.com Prion 1
Prion 7:1, 1–5; January/February 2013; © 2013 Landes Bioscience
Mini-REViEW Mini-REViEW
Prions in Neurological Disease
Stanley Prusiner introduced prions in 1982 as the self-replicat-
ing forms of the prion protein that accumulate in certain trans-
missible diseases of the central nervous system, such as scrapie 
and Creutzfeldt-Jakob disease.1 Although prions represent novel 
infectious agents lacking pathogen-encoded nucleic acids, their 
discovery relied upon a century-old paradigm, formalized into 
postulates by Robert Koch, for identifying pathological microbial 
agents. A key concept in Koch’s postulates is that the microbe 
responsible for a given disease must cause that same disease when 
inoculated into a susceptible host. In prion disease, the afflicted 
individual suffers from a progressive deterioration in neurological 
function that culminates, inevitably, in death. By systematically 
sifting through brain extracts from scrapie-infected hamsters, 
Prusiner found that the deadliest inoculates contained fibrillar 
aggregates of a proteolytic fragment of the prion protein, PrP27-
30. We now know that this fragment is derived from the scrapie 
isoform of the prion protein, PrPSc, an aggregated, alternatively 
folded conformer of the cellular prion protein, PrPC.2
In 2000 Lary Walker first demonstrated that intra-cerebral 
inoculations of brain extracts from amyloid plaque-containing 
brain tissue from Alzheimer patients accelerate amyloid plaque 
deposition and β-amyloidosis in transgenic mice expressing 
human Aβ proteins.3 The acceleration of β-amyloidosis by inoc-
ulates containing Aβ fibrils, which form amyloid plaques, has 
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Like patients with prion disease, Alzheimer patients suffer from 
a fatal, progressive form of dementia. There is growing evidence 
that amyloid-β (Aβ) aggregates may be transmissible similar 
to prions, at least under extreme experimental conditions. 
However, unlike mice infected with prion protein (PrP) prions, 
those inoculated with Aβ do not die. The transmission of Aβ 
and PrP thus differs conspicuously in the neurological effects 
they induce in their hosts, the difference being no less than 
a matter of life and death. Far from being a mere academic 
nuance, this distinction between Aβ and PrP begs the crucial 
questions of what, exactly, controls prion toxicity and how 
prion toxicity relates to prion infectivity.
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been replicated in at least four other laboratories using inoculates 
from humans, several lines of plaque-forming transgenic mice 
and, most recently, fibrillar synthetic Aβ aggregates and syn-
thetic Aβ dimers.4-7
While these results indicate that fibrillar conformers of Aβ 
proteins can self-replicate in susceptible hosts, it is still unclear 
whether such replication can be maintained over multiple serial 
passages from one animal to another. The latter is an integral 
part of the definition of a “prion.” For the sake of the following 
discussion, we will refer to PrPSc as the aggregated form of PrPC 
found in transmissible spongiform encephalopathies (TSEs), 
and to “prions” as the infectious agent of TSEs as measured with 
microbiological methods. In this frame of reference, prions are 
composed of PrPSc, but not all PrPSc is necessarily infectious.8
Infectious Agents, Prions and Prionoids
In 1966 Carlton Gajdusek astonished the scientific world with 
the claim that the fatal degenerative disease kuru was transmitted 
through ritualistic cannibalism among the Fore peoples of New 
Guinea;9 the proposal that the elusive infectious agent in kuru 
was a prion was no less surprising. Now, however, the radical 
properties ascribed to prions threaten to undermine the original 
meaning of “infectious agent.” In the following discussion, an 
infectious agent transmits a disease causing deficits in the host 
that are the same as those in the donor and share the same patho-
physiology. Simply put, infectious agents are the biological basis 
of ill health that can be passed between living beings.
Prions fulfill the above definition since they were initially dis-
covered as true infectious agents using microbiological methods. 
However, many other proteins can aggregate into geometrically 
arranged structures that can seed—in vitro and in vivo—com-
partments containing the parent protein in a monomeric soluble 
state.
Simply equating the capability of seeding with the term 
“prion” is an oversimplification. Any inorganic crystal can seed 
a supersaturated solution of its cognate salt, whereas bona fide 
prions have caused epidemics in sheep, cows, mink, felines and 
humans (kuru, as well as iatrogenic and “variant” Creutzfeldt-
Jakob disease). Because of their flagrant infectious traits—com-
municability and contagiousness—the agents of these diseases 
were not recognized as prions for many decades, and many pre-
eminent scientists deemed them to be “slow viruses.”
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mice without changing plaque load.16,17 Compared with the pro-
teins comprising amyloid lesions, prions, and prionoids, relatively 
little is known about *proteins and their mechanisms of action.
By far the best understood among these disorders is famil-
ial ataxia type 1. Ataxin-1 causes familial ataxia type 1 when 
extraneous trinucleotide repeat sequences expand the existing 
polyglutamine tract to form PolyQ/ataxin-1.18 Patients and mice 
expressing PolyQ/ataxin-1 develop nuclear inclusions and pro-
gressive ataxia. PolyQ aggregates are prionoids, since the appli-
cation of PolyQ aggregates to cultured neurons nucleates the 
formation of intracellular PolyQ amyloid.19 In mice carrying a 
knocked-in expanded PolyQ tract, the severity of the neurologi-
cal abnormalities and neurodegeneration corresponds inversely 
with the number of inclusions,20 and the abolition of the inclu-
sions through the mutation of a ubiquitin ligase, which promotes 
the aggregation of misfolded proteins, accelerates the disease.21 
These studies indicate that the elimination of the inclusions will 
not prevent ataxia in familial ataxia type 1.
The conclusion that the removal of the inclusions would not 
cure familial ataxia type 1 prompted Harry Orr and Huda Zoghbi 
to search for the pathogenic form of PolyQ/ataxin-1 causing the 
neurological abnormalities in the disorder. Discovering the mech-
anism by which PolyQ/ataxin-1 damages neurons emerged from 
understanding the normal physiological roles of ataxin-1, which 
is a nuclear protein. The pathogenic form of PolyQ/ataxin-1 is 
not a misfolded form of ataxin-1; it contains no novel second-
ary structures, no β-sheets that are not normally present in the 
brain. Its pathological effects arise from alterations in its bind-
ing affinities with its normal nuclear partners, the transcriptional 
regulator Capicua and the regulator of RNA splicing RMB17,22 
leading to changes in the transcriptome that, presumably, affect 
neuronal function and viability. Thus, the pathogenic form of 
PolyQ/ataxin-1 is not a prionoid; it is neither a misfolded protein 
nor a soluble aggregate of the parent protein. This may prove to 
be a profoundly important lesson for the entire field of neurode-
generative disease research.
A Puzzle and Two Hypotheses
Both patients with prion disease and Alzheimer disease suffer 
from fatal, progressive forms of dementia. However, while mice 
infected with PrP prions die, those inoculated with Aβ prions do 
not. Only two hypotheses can explain the stark contrast between 
the fatality rates caused by PrP and Aβ inoculations in mice.
• Hypothesis 1: All aggregated proteins (prions and pri-
onoids) are bad. Aggregates are pathogenic, but different 
aggregates exert their effects on different cellular pathways. For 
example, the pathogenic pathway for Aβ aggregates in humans, 
distinct from that of PrP prions, may not exist in mice.
• Hypothesis 2: Not all aggregates are bad. Aggregates are 
not invariably pathogenic; rather, variants of parent proteins 
(*proteins) cause the cellular dysfunction that leads to a neuro-
logical illness (Fig. 1). These pathogenic variants need not be 
misfolded or aggregated forms of the parent proteins.
Recent advances in our understanding of the neurotoxicity of 
PrP and Aβ favor Hypothesis 2, as discussed below.
Since none of the newly discovered seeded aggregates have yet 
been shown to be infectious (i.e., communicable or contagious) 
under natural conditions, we deem it prudent to refer to them 
as “prionoids.”10,11 Maintaining a distinction between prions and 
prionoids implies the existence of underlying biological processes 
that govern the natural transmission of diseases between organ-
isms, including the sophisticated mechanisms by which extra-
neural inoculations of prions subvert the immune system to reach 
and damage the brain (reviewed by Aguzzi and Calella12).
Fortunately, there is no indication that such processes exist 
for Aβ prionoids. However, the demonstration of inter-individ-
ual transmissibility would warrant upgrading the status of such 
agents to bona fide prions, as seems very likely to occur in the 
case of AA amyloid.13
Prionoids and Pathogenic Proteins  
in Neurodegenerative Diseases
Prior to the era of molecular genetics, neurodegenerative diseases 
of the elderly were defined by the types of misfolded proteins that 
accumulate as insoluble deposits in the brain. The deposits con-
sisted of highly ordered stacks of β-sheets, which is the physical 
definition of amyloid. Each type of amyloid resides in a charac-
teristic nuclear, cytoplasmic or extracellular compartment. With 
the advent of molecular genetics came the discovery of causal 
genes linked to many of these neurodegenerative diseases and, in 
a remarkably large number of instances, a given gene encoded the 
very protein comprising the amyloid fibrils that characterized the 
neuropathology in the disease.
These diseases became known as protein misfolding disor-
ders, because the causal genes encoded the misfolded proteins 
comprising the amyloid lesions. In every instance, the misfolded 
proteins acquire secondary structure—β-sheets—that is absent 
under normal conditions. Protein misfolding in neurodegenera-
tive diseases refers to conditions in which parent proteins take on 
novel β-sheet secondary structure. The acquisition of novel sec-
ondary structure distinguishes protein misfolding disorders from 
other diseases caused by mutations that alter protein conforma-
tion, such as sickle cell anemia.
With the exception of PrPSc, there is no experimental evidence 
that the prions or prionoids in neurodegenerative diseases are the 
pathogenic proteins [star (*) proteins] inducing the neurological 
deterioration that devastates patients. For a hundred years, neu-
rofibrillary tangles—the intracellular amyloid inclusions that 
form when tau takes on novel β-sheet structure—were believed 
to induce neuron death and impair cognition. However, in 2005 
this hundred year-old hypothesis was disproven when it was shown 
that reducing soluble tau in a neurodegenerative mouse model with 
neurofibrillary tangles led to the cessation of neuron loss and the 
improvement of memory function, in spite of the startling obser-
vation that the neurofibrillary tangles kept accumulating, remi-
niscent of prionoids.14 The negative case for β-amyloid plaques 
containing *proteins stems from multiple lines of evidence, includ-
ing the failure of Alzheimer patients to improve following Aβ 
immunotherapy that nonetheless successfully removed amyloid 
plaques,15 and the ability of immunotherapy to reverse deficits in 
www.landesbioscience.com Prion 3
presence of Aβ prionoids. It is astonishing that the accumulation 
of Aβ prionoids in the vast majority of mice does not lead to overt 
neurodegeneration, except in the immediate vicinity of amyloid 
plaques.28-30 In mice lacking nitric oxide synthase 2, the accumu-
lation of Aβ prionoids is associated with neuron death in the CA3 
but not the CA1 hippocampal subfield,31 but in humans CA3 is 
spared while CA1 is not,32 calling into question the relevance of 
this form of neuron death. Whether neuron death in this model 
is due to Aβ prionoids is also unknown. Fatality, when present, 
is strain-dependent, and can occur in the absence of amyloid for-
mation, suggesting the existence of a neurotoxic species, which 
may not necessarily be congruent with the self-propagating spe-
cies.33 The biochemical identity and cellular effects of this form 
of Aβ remain unknown.
Two types of cognitive dysfunction develop in mice over pro-
ducing Aβ. One type is found in mice with aggressive amyloid 
deposition—an excessive amount of Aβ prionoids—in which 
the amassed amyloid plaques and their surrounding cytopathol-
ogy act like a gigantic space-occupying lesion in the brain.28 No 
neurons remain within plaque cores, and tortuous, dystrophic 
neurites and dendrites partially denuded of spines reside in the 
50-micron halo surrounding the cores (reviewed by Ashe and 
Zahs34). It is therefore not surprising that, beyond a certain 
threshold, cognition varies inversely with plaque load. However, 
the density of amyloid plaques required to produce this effect is 
rarely reached in Alzheimer disease, which may explain why the 
Neurotoxicity of PrP
In prion disease catastrophic brain dysfunc-
tion is associated with a global decrease in 
protein production, resulting from the dys-
regulation of eIF2a, a mammalian translation 
initiation factor.23 This fascinating discovery 
is presumably the mechanism by which PrP 
prions ultimately induce neurotoxicity.
However, eIF2a is localized within the 
cytosol whereas infectious prions are extracel-
lular. Therefore, we are still left wondering 
how prions containing pathologically aggre-
gated PrPSc can possibly exert actions that orig-
inate from the extracellular milieu, derange 
protein folding in the endoplasmic reticulum, 
induce a surprisingly vigorous unfolded pro-
tein response, and eventually quench cytosolic 
translation of proteins. It is hard not to con-
clude that eIF2a repression likely represents a 
downstream effector of a pathogenic cascade 
that is initiated by molecularly and topologi-
cally distant events.
There has been recurrent discussion as to 
whether the self-replicating material in prion 
disease (the “prion”) is physically identical 
with the neurotoxic entity. In this context, 
John Collinge has recently proposed the term 
“PrPL” to denote a hypothetical moiety that 
may be neurotoxic yet differs from PrPSc.24 
However, the idea that PrP may produce neurological disease 
without the generation of infectivity dates back to 1990 when 
transgenic mice that spontaneously developed prion disease were 
created. These mice expressed PrP carrying a mutation linked to 
a familial prion disease, developed ataxia, lethargy and rigidity, 
and invariably died, but their brains contained few or no infec-
tious prions, suggesting that “an inborn error of PrP metabolism 
could produce neurologic disease without the generation of infec-
tivity.”25 It is possible, and indeed very likely in our view, that PrPSc 
and the various non-infectious neurotoxic variants of PrP, which 
include PrP with supernumerary octapeptide repeats26 and PrP 
versions with interstitial deletions of the “hinge” region between 
the unstructured N-terminus and the globular domain,27 activate 
neurotoxic pathways converging with those triggered by prion 
infection (Fig. 2).
Neurotoxicity of Aβ
Our understanding of the neurotoxicity of Aβ lags behind that 
of PrP, because animal models that recapitulate all the facets of 
Alzheimer disease, which are needed to assay the human rele-
vance of pathological Aβ, do not exist. In humans, the patho-
logical transformation of Aβ initiates a process that involves the 
accumulation of amyloid plaques and often leads to a fatal neu-
rodegenerative condition. In mice, the formation of pathologi-
cal Aβ may induce amyloid plaque deposition, which reflects the 
Figure 1. Prions, prionoids and pathogenic proteins in neurodegenerative diseases. PrPSc 
is considered to be the transmissible agent of the prion causing scrapie, Creutzfeldt-Jakob 
disease and related spongiform encephalopathies. nucleating fibrillar protein aggregates 
(“prionoids”) are found in many neurodegenerative diseases. With the exception of 
PrPSc, there is little evidence in mice or humans linking prionoids in the brain to the 
pathophysiological processes that cause the disorders connected with these proteins. 
instead, accumulating data indicate that the brain dysfunction and neurological signs 
associated with these illnesses are caused by non-fibrillar variants of the parent proteins 
(*proteins). in the case of Aβ, brain dysfunction in mice and CSF tau abnormalities in humans 
are strongly associated with a soluble 56-kDa assembly, Aβ*. The existence of other Aβ* 
molecules has not been excluded. The *proteins need not be misfolded in the sense of 
adopting novel secondary structure, which invariably involves β-sheets. PolyQ/ataxin-1 is 
the best example. Distinguishing between prionoids and *proteins, and understanding how 
*proteins cause neurological illness, will advance our progress in treating these profoundly 
devastating and fatal disorders.
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unpublished data). Tau is released into the CSF, 
through a process that remains unclear, when 
neurons malfunction. CSF tau correlates weakly 
or not at all with CSF Aβ1–42, which reflects 
β-amyloidosis and Aβ prionoids.
Although it was tempting to postulate that 
Aβ*56 triggers a sequence of events that leads to 
the conversion from asymptomatic aging to mild 
cognitive impairment or Alzheimer disease, which 
coincides with the onset of overt neurodegenera-
tion and neuron loss, this prediction was not borne 
out in a large longitudinal study (Handoko M, 
Grant M, Petersen R and Ashe K, unpublished 
data). Thus, Aβ*56 disrupts neuronal function 
in mice and is linked to neuronal malfunction in 
humans, but is insufficient to induce overt neuro-
degeneration in either species.
In the absence of animal models, harbor-
ing Alzheimer-related mutations exclusively, that 
exhibit the full spectrum of disease, beginning 
with subtle neuronal dysfunction and culminat-
ing with fatal cognitive devastation, the question 
of whether asymptomatic β-amyloidosis requires 
Aβ*56 to develop into full-blown Alzheimer dis-
ease cannot be addressed experimentally. It is pos-
sible that one or more non-prionoid form of Aβ 
triggers neuronal dysfunction and neurodegen-
eration in Alzheimer disease. Discovering these 
pathogenic forms will depend upon the creation of high fidelity 
model systems of Alzheimer disease.
Conclusion
In bona fide prion diseases, a very large body of evidence links the 
aggregated form of PrP, PrPSc, to both prion infectivity and prion 
neurotoxicity. However, non-infectious, yet neurotoxic, variants 
of PrP occur naturally and more such variants have been con-
structed experimentally, indicating that the phenotypic expres-
sion typical of prion diseases can be triggered by events occurring 
downstream of prion infection. There is little evidence in mice 
or humans linking the neurological effects of Aβ to the nucleat-
ing forms of this protein, while emerging data point to a specific 
non-nucleating form of Aβ, Aβ*56, that produces some of the 
neurological signs of disease. However, Aβ*56 is not sufficient to 
induce the inexorable neurological deterioration that character-
izes Alzheimer disease, indicating that other critical factors or 
forms of Aβ work in collaboration with Aβ*56 to destroy the 
brain. Curing prion and Alzheimer disease will depend upon 
developing a deeper understanding of the pathogenic forms of 
PrP and Aβ that cause the brain dysfunction underlying these 
deadly illnesses.
links between plaques and neuron loss or cognition are tenuous at 
best.35,36 An excessive accumulation of Aβ prionoids in mice can 
result in cognitive deficits that are related to the space-occupying 
effects of the amyloid plaques, but this is distinct from the mech-
anism by which most of the neuronal dysfunction and neurode-
generation occurs in humans with β-amyloidosis or Alzheimer 
disease.
The other type of cognitive dysfunction occurs independently 
of plaques or neuron loss, and appears to be due to a non-fibrillar 
56-kilodalton Aβ assembly termed Aβ*56.37 Aβ*56 is a putative 
dodecamer most likely formed by the clustering of four Aβ tri-
mers. Isolates of fibrillar Aβ in the brain do not contain Aβ*56 
(Liu P and Ashe K, unpublished data). It is unlikely that Aβ*56 
acquires novel β-sheet structure, because the compositional unit, 
Aβ trimers, is present even in young mice.37 The absence of novel 
β-sheet structure in Aβ*56 argues against it being a prionoid, 
although formal demonstration will require transmission experi-
ments. Aβ*56 induces no overt neurodegeneration, and yet alters 
cognition by disrupting long-lasting synaptic plasticity by an as 
yet unknown mechanism.38 In humans, Aβ*56 can be measured 
in the CSF, where it increases with normal aging and correlates 
moderately strongly with the microtubule-binding protein tau 
(M. Handoko, M. Grant, A. Wallin, K. Blennow and K. Ashe, 
Figure 2. The cellular prion protein is absolutely required for the toxicity of infectious 
prions (A),39 implying that PrPSc exerts neurotoxicity by docking to PrPC (B). This toxicity 
may also be elicited by PrP variants occurring naturally, such as PrP carrying supernu-
merary octapeptide repeats (C), or experimentally constructed toxic variants such as PrP 
versions carrying deletions of the hinge region (D). it was recently discovered that prion 
infection results in a chain of events that ultimately quenches protein translation,23 but 
it remains to be seen whether the toxicity elicited by PrP mutants (C and D) utilizes the 
same pathway.
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